PDCD1 and neoplasm: The inhibition of PD-1/PD-L1 pathway using monoclonal antibodies (mAbs) results in the reversal of the exhausted T-cell phenotype and thereby enabling tumor-reactive T-cells to recognize tumor antigens, providing a rationale for cancer immunotherapy [8].